Pharmaceutical Development of Film-Coated Mini-Tablets with Losartan Potassium for Epidermolysis Bullosa
Epidermolysis bullosa is a genetically heterogenous skin fragility disorder with multiorgan involvement appearing already in newborn children. Severe progressive fibrosis follows skin blistering, mucosa lesions, and wound healing, favouring development of highly aggressive squamous cell carcinomas....
Main Authors: | Valentinë Elezaj, Ard Lura, Luis Canha, Jörg Breitkreutz |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/3/570 |
Similar Items
-
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
by: Alexander Nyström, et al.
Published: (2015-07-01) -
Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa
by: Grace Tartaglia, et al.
Published: (2023-04-01) -
Dystrophic epidermolysis bullosa in a child
by: Uma Eswara
Published: (2012-01-01) -
“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires
by: May El Hachem, et al.
Published: (2024-04-01) -
Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment
by: Kristine A.U. Pallesen, et al.
Published: (2019-09-01)